用于难以治疗综合征的药物的安全性:使用Eudravigilance数据库进行不成比例分析
Arianna Scala1, Teresa Angela Trunfio1, Chiara Pennisi2
1Department of Public Health, University of Naples Federico II, 80131 Naples, Italy.
Pharmaceuticals (Basel, Switzerland)
|December 31, 2025
概括
这项研究分析了用于辅助药的真实世界的安全数据,包括,大麻和. 结果证实了已知的风险,并强调了难以治疗的综合征患者持续监测的必要性.
科学领域:
- 药物监督 药物监督 药物监督
- 症综合征 症综合征
- 药品安全 药品安全
背景情况:
- 难以治疗的综合征通常出现在儿童早期.
- 这些综合征往往对标准药物治疗有抗性.
研究的目的:
- 为了评估斯特里潘托尔,大麻和芬弗鲁拉胺的安全性.
- 利用现实世界药物监测数据用于耐药性的辅助疗法.
主要方法:
- 来自EudraVigilance数据库的个案安全报告 (ICSR) 的回顾性分析.
- 包括截至2024年第三季度的斯特里宾托尔,大麻和芬拉胺的数据.
- 采用了描述性分析和不成比例度量 (报告概率比率).
主要成果:
- 分析了5986个ICSR:大麻的71.6%,黄胺的14.5%,青醇的13.9%.
- 芬拉胺显示,心脏,血管和呼吸系统疾病的报道增加.
- 大麻二醇与产品问题有关;斯特里宾托尔与受伤,代谢和血液疾病有关.
结论:
- 该研究没有揭示这些药物的新严重安全问题.
- 确认需要对患者进行警的监测,以了解潜在的不良事件.
- 建议进行进一步的前性研究,以完善安全性概况并优化药物利用.
关键词:
不良事件不良事件不良事件在Cannabidiol中使用.不成比例性分析分析性综合征 性综合征欧洲监管局 (eudravigilance) 已经开始芬弗鲁拉胺是一种.这种药物叫做stiripentol.更多相关视频
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
590
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
590
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
790
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
790
Bioequivalence of Drugs: Drugs with Multiple Indications
138
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
138
Therapeutic Drug Monitoring: Affecting Factors
170
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
170
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K


